Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol)

U. Tirelli, D. Crivellari, A. Carbone, A. Veronesi, E. Galligioni, M. G. Trovò, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU]). The Karnofsky performance status was <70 in 62% of the patients. Nineteen patients were classified as being in stage III, three were in stage II, and three were in stage I. All patients had symptomatic and previously untreated MM. In 17 of 21 (80.9%) evaluable patients, an objective response according to Myeloma Task Force criteria was obtained. There was no difference in response rate among patients in the various stages of the disease or according to types of proteins secreted. The median time to obtain an objective response was 2 months and the median duration of the remission is 18+ months. The actuarial median survival was 42 months. In the first 15 months of follow-up, 20% of the patients died. Toxicity was not negligible and was mainly hematologic. One treatment-related death occurred. Our study confirms the efficacy of the M-2 protocol in MM and supports the data reported by the Memorial Hospital group.

Original languageEnglish
Pages (from-to)1971-1073
Number of pages899
JournalCancer Treatment Reports
Volume66
Issue number11
Publication statusPublished - 1982

Fingerprint

Carmustine
Melphalan
Vincristine
Prednisone
Combination Drug Therapy
Multiple Myeloma
Cyclophosphamide
Karnofsky Performance Status
Advisory Committees
M-2 protocol
Prospective Studies
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tirelli, U., Crivellari, D., Carbone, A., Veronesi, A., Galligioni, E., Trovò, M. G., ... Grigoletto, E. (1982). Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Cancer Treatment Reports, 66(11), 1971-1073.

Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). / Tirelli, U.; Crivellari, D.; Carbone, A.; Veronesi, A.; Galligioni, E.; Trovò, M. G.; Tumolo, S.; Grigoletto, E.

In: Cancer Treatment Reports, Vol. 66, No. 11, 1982, p. 1971-1073.

Research output: Contribution to journalArticle

Tirelli, U, Crivellari, D, Carbone, A, Veronesi, A, Galligioni, E, Trovò, MG, Tumolo, S & Grigoletto, E 1982, 'Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol)', Cancer Treatment Reports, vol. 66, no. 11, pp. 1971-1073.
Tirelli, U. ; Crivellari, D. ; Carbone, A. ; Veronesi, A. ; Galligioni, E. ; Trovò, M. G. ; Tumolo, S. ; Grigoletto, E. / Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 11. pp. 1971-1073.
@article{30ac0d6caf5546d08ee4b33691c8ba18,
title = "Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol)",
abstract = "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU]). The Karnofsky performance status was <70 in 62{\%} of the patients. Nineteen patients were classified as being in stage III, three were in stage II, and three were in stage I. All patients had symptomatic and previously untreated MM. In 17 of 21 (80.9{\%}) evaluable patients, an objective response according to Myeloma Task Force criteria was obtained. There was no difference in response rate among patients in the various stages of the disease or according to types of proteins secreted. The median time to obtain an objective response was 2 months and the median duration of the remission is 18+ months. The actuarial median survival was 42 months. In the first 15 months of follow-up, 20{\%} of the patients died. Toxicity was not negligible and was mainly hematologic. One treatment-related death occurred. Our study confirms the efficacy of the M-2 protocol in MM and supports the data reported by the Memorial Hospital group.",
author = "U. Tirelli and D. Crivellari and A. Carbone and A. Veronesi and E. Galligioni and Trov{\`o}, {M. G.} and S. Tumolo and E. Grigoletto",
year = "1982",
language = "English",
volume = "66",
pages = "1971--1073",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "11",

}

TY - JOUR

T1 - Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol)

AU - Tirelli, U.

AU - Crivellari, D.

AU - Carbone, A.

AU - Veronesi, A.

AU - Galligioni, E.

AU - Trovò, M. G.

AU - Tumolo, S.

AU - Grigoletto, E.

PY - 1982

Y1 - 1982

N2 - From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU]). The Karnofsky performance status was <70 in 62% of the patients. Nineteen patients were classified as being in stage III, three were in stage II, and three were in stage I. All patients had symptomatic and previously untreated MM. In 17 of 21 (80.9%) evaluable patients, an objective response according to Myeloma Task Force criteria was obtained. There was no difference in response rate among patients in the various stages of the disease or according to types of proteins secreted. The median time to obtain an objective response was 2 months and the median duration of the remission is 18+ months. The actuarial median survival was 42 months. In the first 15 months of follow-up, 20% of the patients died. Toxicity was not negligible and was mainly hematologic. One treatment-related death occurred. Our study confirms the efficacy of the M-2 protocol in MM and supports the data reported by the Memorial Hospital group.

AB - From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU]). The Karnofsky performance status was <70 in 62% of the patients. Nineteen patients were classified as being in stage III, three were in stage II, and three were in stage I. All patients had symptomatic and previously untreated MM. In 17 of 21 (80.9%) evaluable patients, an objective response according to Myeloma Task Force criteria was obtained. There was no difference in response rate among patients in the various stages of the disease or according to types of proteins secreted. The median time to obtain an objective response was 2 months and the median duration of the remission is 18+ months. The actuarial median survival was 42 months. In the first 15 months of follow-up, 20% of the patients died. Toxicity was not negligible and was mainly hematologic. One treatment-related death occurred. Our study confirms the efficacy of the M-2 protocol in MM and supports the data reported by the Memorial Hospital group.

UR - http://www.scopus.com/inward/record.url?scp=0020429739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020429739&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 1971

EP - 1073

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 11

ER -